MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity

Vaccine

Volumn 29, Issue 3, 2011, Pages 545-557

  Girvan, Rebecca C ^a   Knight, Deborah A ^b   O'loughlin, Chris J ^a   Hayman, Colin M ^c   Hermans, Ian F ^b   Webster, Gill A ^a  

^a AMSC   (New Zealand)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^c CALLAGHAN INNOVATION   (New Zealand)

Author keywords

Bacterial DNA; Microparticle vaccine adjuvant; Muramyl dipeptide; TLR9 ligand

Indexed keywords

ANTIBODY CONJUGATE; BACTERIAL DNA; CELL WALL SKELETON; DNA FRAGMENT; IMMUNOLOGICAL ADJUVANT; MIS 416; MURAMYL DIPEPTIDE; OVALBUMIN; UNCLASSIFIED DRUG; CYTOKINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL SELECTION; CELL SUBPOPULATION; CELL WALL; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; IMMUNOSTIMULATION; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; TH1 CELL; ANIMAL; C57BL MOUSE; CHEMISTRY; DENDRITIC CELL; ENDOCYTOSIS; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; SECRETION; VACCINATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOKINES; DENDRITIC CELLS; DNA, BACTERIAL; ENDOCYTOSIS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; PROPIONIBACTERIUM ACNES; TH1 CELLS; VACCINATION;

EID: 78650520026     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.040     Document Type: Article

References (56)

1. Munz C., Steinman R.M., Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005, 202(July (2)):203-207.
2. Medzhitov R., Janeway C. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000, 173(February):89-97.
3. Gay N.J., Gangloff M. Structure and function of toll receptors and their ligands. Annu Rev Biochem 2007, 76(1):141-165.
4. Fallon P.G., Alcami A. Pathogen-derived immunomodulatory molecules: future immunotherapeutics?. Trends Immunol 2006, 27(10):470-476.
5. Kawai T., Akira S. Signaling to NF-[kappa]B by Toll-like receptors. Trends Mol Med 2007, 13(11):460-469.
6. Foti M., Granucci F., Pelizzola M., Beretta O., Ricciardi-Castagnoli P. Dendritic cells in pathogen recognition and induction of immune responses: a functional genomics approach. J Leukoc Biol 2006, 79(May (5)):913-916.
7. Herre J., Marshall A.S.J., Caron E., Edwards A.D., Williams D.L., Schweighoffer E., et al. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 2004, 104(December (13)):4038-4045.
8. Ulmer J.B., Wahren B., Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006, 12(5):216-222.
9. Tomai M.A., Miller R.L., Lipson K.E., Vasilakos J.P., Woulfe S.L. Immune response modifiers: imiquimod and future drugs for modulating the immune response. Drug Discovery Today: Ther Strategies 2006, 3(3):343-352.
10. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
11. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6(August (8)):769-776.
12. Yeung V.P., Gieni R.S., Umetsu D.T., DeKruyff R.H. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol 1998, 161(October (8)):4146-4152.
13. Ghosh T.K., Mickelson D.J., Solberg J.C., Lipson K.E., Inglefield J.R., Alkan S.S. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-[alpha]. Int Immunopharmacol 2007, 7(8):1111-1121.
14. Merlo A., Calcaterra C., Menard S., Balsari A. Cross-talk between Toll-like receptors 5 and 9 on activation of human immune responses. J Leukoc Biol 2007, 82(September (3)):509-518.
15. Nau G.J., Schlesinger A., Richmond J.F.L., Young R.A. Cumulative toll-like receptor activation in human macrophages treated with whole bacteria. J Immunol 2003, 170(May (10)):5203-5209.
16. Tada H., Aiba S., Shibata K.-I., Ohteki T., Takada H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 2005, 73(December (12)):7967-7976.
17. Bevan M.J. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976, 117(December (6)):2233-2238.
18. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004, 199(June):9-26.
19. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004, 5(December (12)):1219-1226.
20. Benitez-Ribas D., Adema G.J., Winkels G., Klasen I.S., Punt C.J.A., Figdor C.G., et al. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake. J Exp Med 2006, 203(July (7)):1629-1635.
21. Le Bon A., Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14(4):432-436.
22. Beignon A.-S., Skoberne M., Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 2003, 4(10):939-941.
23. Lui G., Manches O., Angel J., Molens J.-P., Chaperot L., Plumas J. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS ONE 2009, 4(9):e7111.
24. Villadangos J.A., Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29(September (3)):352-361.
25. Fujii S., Liu K., Smith C., Bonito A.J., Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004, 199(June (12)):1607-1618.
26. Fujii S., Shimizu K., Smith C., Bonifaz L., Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003, 198(July (2)):267-279.
27. Hermans I.F., Silk J.D., Gileadi U., Masri S.H., Shepherd D., Farrand K.J., et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 2007, 178(March (5)):2721-2729.
28. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003, 171(November (10)):5140-5147.
29. Moretta A., Marcenaro E., Parolini S., Ferlazzo G., Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2007, 15(2):226-233.
30. Macagno A., Napolitani G., Lanzavecchia A., Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol 2007, 28(5):227-233.
31. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26(13):1626-1637.
32. O'Hagan D.T., Singh M., Ulmer J.B. Microparticle-based technologies for vaccines. Methods 2006, 40(1):10-19.
33. Siepmann J., Siepmann F. Microparticles used as drug delivery systems. Colloid Polym Sci. 2006, 15-21.
34. Kirchner H., Glaser M., Herberman R.B. Suppression of cell-mediated tumour immunity by Corynebacterium parvum. Nature 1975, 257(5525):396-398.
35. Takada H., Tsujimoto M., Kotani S., Kusumoto S., Inage M., Shiba T., et al. Mitogenic effects of bacterial cell walls, their fragments, and related synthetic compounds on thymocytes and splenocytes of guinea pigs. Infect Immun 1979, 25(August (2)):645-652.
36. Sirard J.-C., Vignal C., Dessein R., Chamaillard M. Nod-like receptors: cytosolic watchdogs for immunity against pathogens. PLoS Pathog 2007, 3(12):e152.
37. Yang Y., Yin C., Pandey A., Abbott D., Sassetti C., Kelliher M.A. NOD2 pathway activation by MDP or mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem 2007, 282(December (50)):36223-36229.
38. Kerkmann M., Rothenfusser S., Hornung V., Towarowski A., Wagner M., Sarris A., et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of Type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003, 170(May (9)):4465-4474.
39. Samuel C.E. Innate immunity minireview series: making biochemical sense of nucleic acid sensors that trigger antiviral innate immunity. J Biol Chem 2007, 282(May (21)):15313-15314.
40. Morris D.L. Quantitative determination of carbohydrates with Dreywood's anthrone reagent. Science 1948, 107(March (2775)):254-255.
41. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T-cell receptor antagonist peptides induce positive selection. Cell 1994, 76(January (1)):17-27.
42. Lee A., Farrand K.J., Dickgreber N., Hayman C.M., Jurs S., Hermans I.F., et al. Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr Res 2006, 341(December (17)):2785-2798.
43. Brown D.M., Fisher T.L., Wei C., Frelinger J.G., Lord E.M. Tumours can act as adjuvants for humoral immunity. Immunology 2001, 102(4):486-497.
44. Howe J.M., Featherston W.R., Stadelman W.J., Banwart G.J. Amino acid composition of certain bacterial cell-wall proteins. Appl Environ Microbiol 1965, 13(September (5)):650-652.
45. Grutters M., Raaphorst Wv, Epping E., Helder W., Leeuw JWd, Glavin D.P., et al. Preservation of amino acids from in situ-produced bacterial cell wall peptidoglycans in Northeastern Atlantic continental margin sediments. Limnol Oceanogr 2002, 47(5):1521-1524.
46. Cleveland M., Gorham J., Murphy T., Tuomanen E., Murphy K. Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect Immun 1996, 64(June (6)):1906-1912.
47. Yasuda H., Leelahavanichkul A., Tsunoda S., Dear J.W., Takahashi Y., Ito S., et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008, 294(May (5)):F1050-F1058.
48. Irvine K., Chamberlain R., Shulman E., Rosenberg S., Restifo N. Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J Natl Cancer Inst 1997, 89(March (5)):390-392.
49. Magalhaes J.G., Fritz J.H., Le Bourhis L., Sellge G., Travassos L.H., Selvanantham T., et al. Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 2008, 181(December (11)):7925-7935.
50. Krieg A. Signal transduction induced by immunostimulatory CpG DNA. Springer Seminars Immunopathol 2000, 22(1):97-105.
51. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434(7034):772-777.
52. Mailliard R.B., Son Y.-I., Redlinger R., Coates P.T., Giermasz A., Morel P.A., et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003, 171(September (5)):2366-2373.
53. Yi A.-K., Yoon J.-G., Yeo S.-J., Hong S.-C., English B.K., Krieg A.M. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 2002, 168(May (9)):4711-4720.
54. Kalinski P., Vieira P.L., Schuitemaker J.H.N., de Jong E.C., Kapsenberg M.L. Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97(June (11)):3466-3469.
55. Luft T., Luetjens P., Hochrein H., Toy T., Masterman K.-A., Rizkalla M., et al. IFN-{alpha} enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 2002, 14(April (4)):367-380.
56. Tacken P.J., de Vries I.J.M., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7(10):790-802.